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Abstract
Guidelines state that the CCR5-inhibitor Maraviroc should be prescribed to patients infected with R5-tropic HIV-1 only. Therefore, viral
tropism needs to be assessed phenotypically or genotypically. Preliminary clinical trial data suggest that genotypic analysis in triplicate is
associated with improved prediction of virological response by increasing the detection of X4-tropic variants. Our objective was to eval-
uate the impact of triplicate genotypic analysis on prediction of co-receptor usage in routine clinical practice. Samples from therapy-
naive and therapy-experienced patients were collected for routine tropism testing at three European clinical centres. Viral RNA was
isolated from plasma and proviral DNA from peripheral blood mononuclear cells. Gp120-V3 was ampliﬁed in a triplicate nested RT-
PCR procedure and sequenced. Co-receptor usage was predicted using the Geno2Pheno[coreceptor] algorithm and analysed with a false-
positive rate (FPR) of 5.75%, 10%, or an FPR of 20% and according to the current European guidelines on the clinical management of
HIV-1 tropism testing. A total of 266 sequences were obtained from 101 patient samples. Discordance in tropism prediction for the
triplicates was observed in ten samples using an FPR of 10%. Triplicate testing resulted in a 16.7% increase in X4-predicted samples and
to reclassiﬁcation from R5 to X4 tropism for four cases rendering these patients ineligible for Maraviroc treatment. In conclusion, tripli-
cate genotypic tropism testing increases X4 tropism detection in individual cases, which may prove to be pivotal when CCR5-inhibitor
therapy is applied.
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Introduction
Maraviroc (MVC) is the ﬁrst available antiretroviral drug tar-
geting a human receptor. It binds to the CCR5 co-receptor
thereby inhibiting replication of CCR5 using (R5-tropic) HIV-
1 [1,2]. MVC has been approved for HIV-1-infected patients
that exclusively harbour R5-tropic viruses and is licensed in
Europe for therapy-experienced patients and in the USA for
both therapy-experienced and therapy-naive patients. As
MVC has no antiretroviral effect on strains using the CXCR4
co-receptor (X4-tropic), determination of co-receptor usage
(viral tropism testing) is needed to exclude the presence of
X4-tropic HIV-1 strains. For determination of viral tropism
several phenotypic and genotypic assays have been devel-
oped. Among phenotypic tropism tests, the ‘enhanced sensi-
tivity Troﬁle assay’ (ESTA; Monogram Biosciences, San
Francisco, CA) is most often used [3,4]. However, for clinical
centres, ESTA has several limitations: testing is only per-
formed in California (USA), resulting in logistical problems,
long turnaround time and high costs. Furthermore, the assay
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is only available in Europe for samples with HIV RNA
‡1000 copies/mL. For these reasons tropism testing is
increasingly performed using genotypic assays.
Genotypic tropism tests analyse the sequence of the HIV-
1 envelope gp120 variable 3 (V3) loop, the main determinant
for co-receptor usage. To predict viral tropism the gener-
ated V3 sequences are interpreted using publicly available
algorithms, such as Geno2Pheno[coreceptor] (G2P) and posi-
tion-speciﬁc scoring matrices (PSSMX4-R5) [5,6]. Genotypic
tropism testing can be applied on population sequences
obtained from either HIV RNA or HIV proviral DNA. The
latter is recommended if HIV RNA levels are below the level
of reliable ampliﬁcation [7]. Population sequencing, the most
frequently used method of genotypic tropism testing, is ham-
pered by limited sensitivity for detecting minority X4-tropic
strains in the quasi-species. As such, minority X4-tropic vari-
ants may remain undetected when they represent <10–25%
of the total population [8–10].
Despite limitations in sensitivity compared with ESTA,
population genotypic tropism testing demonstrated equal
predictive value for virological outcome of MVC-containing
therapy in antiretroviral naive individuals [11]. In this particu-
lar retrospective analysis a genotypic testing procedure was
performed in triplicate to increase detection of minority X4
populations.
The rationale for performing genotypic tropism testing in
triplicate, instead of using a single procedure as usually per-
formed for resistance testing on pol, is based on differences
in selective pressure on the viral envelope protein compared
with pol, which are reﬂected by the nine-fold higher nucleo-
tide substitutions/site/year in env [12]. The relatively high lev-
els of variation in env may be better captured in a triplicate
procedure.
In therapy-experienced patients, re-analysis of three clini-
cal trials demonstrated that triplicate genotypic tropism test-
ing increased the number of X4-predicted samples [13].
Preliminary data suggest that testing in triplicate has a beneﬁ-
cial effect on predicting clinical outcome of MVC-containing
regimens [13].
However, in clinical cohort studies triplicate genotypic
tropism testing is not performed routinely. Still a good cor-
relation between genotypic tropism testing and ESTA in pre-
dicting virological outcome to MCV-containing therapy has
been observed [14–17]. As such, the added value of triplicate
testing in routine care is still under debate.
In the absence of a direct comparison of single and tripli-
cate test procedures in clinical practice, the recently formu-
lated European guidelines advise triplicate testing with a
false-positive rate (FPR) of 10%. If single testing is performed
then a more conservative FPR of 20% for RNA samples with
a viral load <1000 copies/mL and for proviral DNA samples
is recommended [7].
We investigated the inﬂuence of triplicate testing on tro-
pism prediction during routine clinical practice in three Euro-
pean clinical centres.
Materials and Methods
Patient samples on which routine tropism testing was per-
formed in clinical practice were randomly selected from
three European centres. HIV-1 plasma RNA levels and
counts of CD4+ cells/mm3 at nadir and at time of sampling
were collected, HIV proviral DNA was not measured. HIV-1
pol subtyping was based on IDNS (Smartgene, Lausanne,
Switzerland) or the Rega HIV-1 subtyping tool [18].
Viral RNA, DNA isolation
Viral RNA was isolated from 200–500 lL EDTA-plasma with
the Viroseq HIV-1 sample preparation module (Abbott, Hoof-
dorp, the Netherlands) or a high pure viral RNA kit (Roche,
Vilvoorde, Belgium). If no plasma was available or the HIV
RNA level was below the level of ampliﬁcation, proviral DNA
was extracted from 1.0E7 peripheral blood mononuclear cells
with QIAamp DNA Blood Mini Kit (QIAGEN, Madrid, Spain).
For each sample, one isolation was performed. Subsequent
processing of the samples, ampliﬁcation and sequencing, were
performed in triplicate. In each isolation and ampliﬁcation
round two or three negative controls were included, depend-
ing on the number of isolations and ampliﬁcations.
Viral RNA ampliﬁcation
For ampliﬁcation of the V3-loop, two in-house protocols
were used. Protocol one; 10 lL of RNA, with primers
6206V3F 5¢-AGAGCAGAAGACAGTGGCAATGAGAGT
GA-3¢, 7785R 5¢-AGTGCTTCCTGCTGCTCCYAAGAA
CCC-’3 (Titan One Tube RT-PCR kit, Roche, Woerden, the
Netherlands) for RT-PCR. Subsequently a nested-PCR was
performed using primers 6658F 5¢-TGGGATCAAAGCCT
AAAGCCATGTG-’3, 7371R 5¢-GAAAATTCCCCTCCACAA
TT-’3 (Expand High-Fidelity PCR-System, Roche, Woerden,
the Netherlands). Sequencing was performed with primers
6957F 5¢-GTACAATGTACACATGGAAT-’3 and 7371R or
V3-4 5¢-ACAGTACAATGTACACATGGAATTA-3¢ and V3-3
5¢-AATTCCCCTCCACAATTAAAASTGTG-3¢ (Big dye Ter-
minator Cycle seq kit v3,1, Applied Biosystems, Nieuwekerk
ad IJsel, the Netherlands). Protocol two; for the RT-PCR
10 lL RNA and a mixture of the primers sense ENV_11
5¢-GGATATAATCAGYYTATGGGA-3¢, antisense ENV_22
5¢-GGTGGGTGCTAYTCCYAITG-3¢, sense-ENV1 5¢-GAG-
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GATATAATCAGTTTATGG-3¢ and antisense-7294 5¢-
GGTGGGTGCTATTCCTAATGG-3¢ (Titan One Tube RT-
PCR kit, Roche, Vilvoorde, Belgium) were used. These primer
mixtures cover a broader range of HIV variants The nested-
PCR was performed using primers sense-ENV_33 5¢-GAT
CAAAGCCTAAARCCATGT-3¢, antisense-ENV_44 5¢-CTC
CAATTGTCCYTCATHTYTCC-3¢, sense-ENV2 5¢-GA
TCAAAGCCTAAAGCCATG-3¢ and antisense-7238 5¢-ACT
TCTCCAATTGTCCCTCATAT-3¢ with AmpliTaq DNA
polymerase (Applied Biosystems, Halle, Belgium). Ampliﬁed
product was sequenced with primers sense-6951 5¢-AG
YRCAGTACAATGYACACATGG-3¢, sense-6690 5¢-TCAA
CHCAAYTRCTGTTAAATGG-3¢ and antisense-7336 5¢-ATT
TCTRGRTCYCCICCYG-3¢ (Big dye Terminator Cycle seq
kit v3,1, Applied Biosystems).
Proviral DNA ampliﬁcation
For ampliﬁcation 3 lL DNA was used to amplify full-length
envelope with Platinum Taq DNA Polymerase High Fidelity
(Invitrogen, Barcelona, Spain) using primers 5677U24 5¢-ATG
GCTTAGGGCAACATATCTATG-3¢ and 9687L24 5¢-
CTGAGGGATCTCTAGTTACCAGAG-3¢ or primers
5954U29 5¢-CACCTAGGCATCTCCTATGGCAGGAA
GAAG-3¢ and 8904L22 5¢-GTCTCGAGATACTGCTCCC
ACCC-3¢. Nested-PCR using primers 5954U29 5¢-CACCTA
GGCATCTCCTATGGCAGGAAGAAG-3¢ and 8904L22 5¢-
GTCTCGAGATACTGCTCCCACCC-3¢ or 6373U22
5¢-CCACTCATTTTGTGCATCAGA-3¢ and 7855L25 5¢-AAY
TGTCTGCCTGTACCGTCAGCG-3¢ (Platinum Taq DNA
Polymerase High Fidelity, Invitrogen). Sequenced using
primers 7002U20 5¢-CTGTTAAATGGCAGTCTAGC-3¢ and
7374L25 5¢-AGAAAAATTCYCCTCYACAATTAAA-3¢, or
6959U25 5¢-ACAATGYACACATGGAATTARGCCA-3¢ and
7365L21 5¢-CCCCTCCACAATTAAAACTGT-3¢ (Big dye Ter-
minator Cycle seq kit v3.1, Applied Biosystems, Madrid, Spain).
Tropism prediction
Nucleotide sequence tropism prediction was performed
in silico using G2P and an FPR of 5.75%, 10%, 20% and accord-
ing to the current European guidelines [7]. For web-PSSMX4-R5
the amino acid sequence was used. In the case of mixtures all
possible amino acid sequences were analysed and the highest
value was reported (R5 prediction: £)6.69, X4: ‡)2.88, the
11/25 rule was applied at intermediate values) [19]. If an iso-
late was predicted to be X4-tropic in at least one of the three
tests the viral population was reported to be X4-tropic.
Statistical analysis
Pearson chi-squared test was used to compare the ratio X4-
predicted sequences between low (<350) and high (‡350)
CD4+ cells/mm3, to compare the ratio of X4-predicted
sequences of G2P versus PSSMX4-R5, and to evaluate the
ratio and number of X4-predicted sequences, and samples
between single, duplicate or triplicate testing. Mann–Witney
U-test was used to compare viral RNA load between sam-
ples with or without ampliﬁcation failure. Furthermore, data
were randomized with randperm in MATLAB 2010b. Values
below 0.05 were regarded statistically signiﬁcant.
Results
The majority of 101 patients (70) were infected with subtype
B, followed by: C (6), CRF02_AG (6), CRF01_AE (5), A (4),
A1 (2), G (1), H (1), J (1), CRF15_01B (1), CRFAB (1),
CRF30 (1), CRF18_cpx (1) and one unclassiﬁed strain. The
median viral load was 8.35 E3 copies/mL HIV RNA (inter-
quartile range (IQR) 7.26 E4). The median CD4+ T-cell count
at time of sampling was 422 CD4+ (IQR 439) and the median
nadir CD4+ T-cell count was 310 (IQR 261) cells/mm3. Nei-
ther low CD4+ cell-count at time of sampling (p 0.636) nor
low nadir CD4+ count (p 0.462) was associated with either
X4 or R5 prediction. Tropism was predicted using two inter-
pretation algorithms; G2P and PSSMX4-R5. Using an FPR of
10% the number of X4-predicted sequences did not signiﬁ-
cantly differ between G2P and PSSMX4-R5 (p 0.186), 28
sequences were predicted to be X4-tropic in G2P and R5-
tropic in PSSMX4-R5. Conversely, 15 sequences were pre-
dicted to be R5-tropic in G2P and X4-tropic in PSSMX4-R5.
As G2P is the most commonly used interpretation algorithm
in clinical practice in Europe further analysis was performed
with G2P only.
Using a triplicate procedure a total of 266 (87.8%)
sequences were generated (156 from 58 viral RNA samples
and 110 from 43 proviral DNA samples) (Fig. 1). Ampliﬁca-
tion failures were observed in 14% of proviral DNA samples
and in 10% of viral RNA samples. Ampliﬁcation failures were
not speciﬁcally associated with low viral RNA load (p 0.249).
Median viral RNA load of samples with an ampliﬁcation fail-
ure was 7.9 E3 (IQR 1.221 E5) compared with 8.7 E3 (IQR
5.479 E4) for samples with no ampliﬁcation failure.
The majority of sequences had an FPR above 10%
(n = 202, 75.9%). After dividing the data into 10% FPR incre-
ments, these sequences are distributed throughout the differ-
ent categories. The remaining 24.1% (n = 64) fall into the
0–10% FPR increment, which therefore was the largest cate-
gory (Fig. 2). Using single genotypic tropism testing successful
tropism results were generated for 92.1% of the samples.
The success rate increased into 100% tropism results when
tested in duplicate and triplicate. Pooled analysis of triplicate
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sequence data from individual patient samples resulted in an
X4 prediction in 25.9% of the viral RNA samples and 30.2%
of the viral DNA samples (FPR 10%; p 0.628) (Fig. 1a).
Samples for which one of the sequences resulted in an R5
prediction while at least one of the other sequences yielded
X4 results, were considered discordant. Analysis of the data
(a)
(b)
(c)
(d)
FIG. 1. A total of 101 patient samples tested in a single versus triplicate genotypic tropism procedure (58 viral RNA samples and 43 proviral DNA
samples). VL = HIV-1 RNA level copies/mL, number of successfully analysed sequences are listed. Tropism was predicted using a false-positive rate
(FPR) of 5.75% (a), 10% (b), 20% (c) or according to the current European guidelines (d) [7]. Percentage X4-predicted samples is depicted.
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with an FPR of 10% resulted in ten discordant tropism
results, four viral RNA and six proviral DNA samples (9.9%)
had discordant tropism results (Fig. 1).
Discordance does not always result in reclassiﬁcation of
the tropism report. If a population is predicted to be X4-
tropic in the ﬁrst replicate, ﬁnding an R5-tropic virus in the
second or third replicate will not change the tropism predic-
tion.
Therefore we analysed for each individual patient sample
the inﬂuence of triplicate testing on the reported tropism
result. If only the ﬁrst replicate was taken into account, 24
samples (both RNA and DNA samples) were predicted to
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FIG. 2. Distribution of Geno2Pheno[coreceptor] results of 266 sequences obtained from 101 patient samples. Black bars represent proviral DNA
sequences, striped bars represent viral RNA sequences. Distribution of 0>10 false-positive rate (FPR) is also subdivided in categories 0>2.5,
2.5>5 and 5>10.
TABLE 1. Overview of reclassiﬁed samples using a triplicate tropism procedure. X4 prediction is given in red and R5 predic-
tion in green, – indicates ampliﬁcation failure and NA = not assessed. Guidelines: European guidelines on clinical management
of HIV-1 tropism testing [7]
aThe European guidelines advise a false-positive rate (FPR) of 10% for triplicate procedures. For a single procedure an FPR of 20% for RNA samples with a viral load
<1000 copies/mL and for proviral DNA samples is advised.
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be X4-tropic (23.8%). Adding the second replicate increased
the number of X4-predicted samples to 27 (26.7%) and addi-
tion of the third replicate resulted in 28 samples with X4
tropism results (27.7%) (Fig. 1). Hence, triplicate testing
using an FPR of 10% resulted in a 16.7% increase of X4-pre-
dicted samples. This corresponds to a 4% increase in X4
prediction for the total study population (p 0.730) and
reclassiﬁcation from R5 to X4 tropism in four patients (RNA
n = 2; DNA n = 2) (Table 1). Additionally we analysed the
data with three random sets of ﬁrst replicates using an FPR
of 10%. These three data sets resulted in ten discordant
samples with four, ﬁve or eight reclassiﬁcations from R5 to
X4 tropism, respectively (p ‡0.278). Randomizing the order
of replicates did not inﬂuence our results.
Triplicate analyses using a more conservative 20% FPR
increased the total number of discordant samples to 16
(15.8%) (RNA n = 7; DNA n = 9) (Fig. 1) and the number of
reclassiﬁcations from R5 to X4 tropism to seven (6.9%,
p 0.353) (Table 1). Analysis of the sequence replicates in a
different order did not signiﬁcantly change the level of reclas-
siﬁcations (all p values ‡0.310). The number of discordant
samples did not signiﬁcantly differ in proviral DNA samples
(low viral load) or RNA samples (high viral load) (p ‡0.228
depending on FPR).
We also analysed the samples according to the European
guidelines for clinical management of HIV-1 tropism testing
[7]. In this analysis the ﬁrst replicate resulted in 28 (27.7%)
samples predicted to be X4-tropic. Triplicate genotypic tro-
pism testing did not change the overall number of X4-pre-
dicted samples (Fig. 1). However, this analysis resulted in
eight discordant samples (RNA n = 4, DNA n = 4). Further-
more, two viral RNA samples and two proviral DNA sam-
ples were reclassiﬁed from R5-tropic to X4-tropic and four
proviral DNA samples were reclassiﬁed from X4-tropic to
R5-tropic (Table 1). In literature, a low FPR of 5.75% was
found to be a good predictor for response to MVC treat-
ment in phenotypically pre-screened patients [20]. In general,
application of a lower FPR results in less frequent prediction
of X4 virus and therefore a decreased level of discordance.
In our data set triplicate testing with an FPR of 5.75% yielded
ﬁve discordant samples (RNA n = 2, DNA n = 3) resulting in
reclassiﬁcation from R5 to X4 tropism in only one patient
(p 0.995) (Fig. 1).
Discussion
We evaluated the added value of triplicate versus single test-
ing on genotypic tropism prediction in routine clinical prac-
tice. Co-receptor usage of virus isolates from 101 patient
samples was predicted after V3 sequencing and applying pub-
licly available and commonly used interpretation algorithms.
In this study, patient samples with a broad range of HIV
RNA plasma levels as well as proviral DNA samples were
analysed with G2P with an FPR of 5.75%, 10%, 20% and
according to current European guidelines on tropism testing.
A considerable number of samples with discordant tripli-
cate results was observed. In one out of every ten samples
X4-predicted as well as R5-predicted sequences were
detected. However, in only half of these cases did the dis-
cordance result in a reclassiﬁcation of the ﬁnal tropism call
from R5 to X4.
One could argue that in samples with a low viral input the
observed discordance in the triplicate analyses results from
stochastic errors in sampling and ampliﬁcation. However, the
number of discordant results did not signiﬁcantly differ
between samples with low or high viral load. Therefore it
seems more likely that the overall high levels of variation in
env is the reason for the observed discordance in the tripli-
cate analysis of viral tropism. Detection of nucleotide mix-
tures in a sequence complicates the tropism prediction. In
the G2P algorithm nucleotide sequences are used as input
and amino acid mixtures are therefore considered. In
PSSMX4-R5 amino acid sequences are used as input and all
possible amino acid combinations have to be considered
manually. Taking mixtures into account may overcall X4 pre-
diction because not every combination may actually be pres-
ent in the viral population. Next generation, ultra-deep
pyrosequencing may partly solve this issue because every
strain is separately sequenced using this technique. Our
results could not be compared with ESTA because almost
half of our samples had a viral load below the minimum
requirement of 1000 copies/mL for European samples.
Our study is the ﬁrst that compares single with triplicate
genotypic tropism testing in clinical practice. A recent study
investigated the added value of tropism determination using
duplicate PCR ampliﬁcation and pooled sequencing. All possi-
ble amino acid sequences of the V3 loop were interpreted
with G2P using an FPR of 10% [21]. The number of X4 tro-
pism results in this particular duplicate approach increased
from 25 to 30 (3.3%), which is in line with our observations.
On the individual patient level, our triplicate procedure
increased the detection of X4 variants, thereby decreasing
the number of patients eligible for MVC treatment. Unfortu-
nately we cannot present clinical outcome data comparing
single with triplicate testing because our study was designed
as a prospective analysis and triplicate testing results were
part of the clinical decision-making. Triplicate testing may
have implications for the efﬁcacy of MVC-containing therapy.
Failure to detect an X4 virus in a single genotypic procedure
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may lead to selection of X4 virus, MVC therapy failure and
loss of backbone activity [22].
In conclusion, independent of the applied FPR, triplicate
testing increased X4 prediction in individual cases. Our
results illustrate that comparison of single with triplicate
ampliﬁcation procedures in relation to clinical outcome data
is urgently needed. Pending these data, we prefer to be con-
servative and increase the sensitivity of genotypic tropism
testing by performing a triplicate procedure in routine clini-
cal practice.
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